PDF herunterladen
Digestive Disease Interventions
DOI: 10.1055/s-0044-1787959
Review Article

Image-Guided Ablation for Cholangiocarcinoma: Current Evidence and Future Directions

Jessica Albuquerque M. Silva 
1   Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Iwan Paolucci
1   Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Kristy K. Brock
2   Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Bruno C. Odisio
1   Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
› Institutsangaben Funding Sources The present manuscript has no funding support.
Researchers on this publication were supported in part by the National Cancer Institute of the National Institutes of Health under award number R01CA235564; the Image Guided Cancer Therapy Research Program at The University of Texas MD Anderson Cancer Center through a generous gift from the Apache Corporation and the Helen Black Image Guided Fund, by the Tumor Measurement Initiative through the MD Anderson Strategic Initiative Development Program (STRIDE), and Siemens Healthineers.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Though the incidence of intrahepatic cholangiocarcinoma (ICC) is rare compared with other malignancies, its prevalence is increasing significantly worldwide. Intrahepatic cholangiocarcinoma is an aggressive tumor, typically presenting at an advanced stage and showing resistance to treatments. The primary cause of mortality is liver failure related to tumor progression with associated parenchymal loss and vascular or biliary compromise. Currently, surgical resection remains the primary curative approach, yet less than 20% of patients are eligible for such treatment, and postoperative rate of recurrence are high. In this context, locoregional therapies such as percutaneous thermal ablation have been shown to be safe and effective for patients with unresectable or recurrent ICCs. This review discusses the clinical application of ablation techniques, as it relates to patient selection and tumor characteristics for the treatment of ICC.

Keywords

ablation techniques - cholangiocarcinoma - liver

Authors' Contributions

1. Contributions to conception and design, acquisition of data, or analysis and interpretation of data: all authors.


2. Drafting and revising the article: J.A.M.S., I.P., B.C.O.


4. Final approval of the version to be published: all authors.




Publikationsverlauf

Eingereicht: 04. April 2024

Angenommen: 30. Mai 2024

Artikel online veröffentlicht:
13. August 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 2018; 288 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 2 Dai YS, Hu HJ, Lv TR, Hu YF, Zou RQ, Li FY. The influence of resection margin width in patients with intrahepatic cholangiocarcinoma: a meta-analysis. World J Surg Oncol 2023; 21 (01) 16
    CrossrefPubMedGoogle Scholar
  • 3 Hu EY, Bhagavatula S, Shi A, Tuncali K, Levesque V, Shyn PB. Image-guided ablation of recurrent or unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2023; 34 (06) 1007-1014
    CrossrefPubMedGoogle Scholar
  • 4 Xiang X, Hu D, Jin Z, Liu P, Lin H. Radiofrequency ablation vs. surgical resection for small early-stage primary intrahepatic cholangiocarcinoma. Front Oncol 2020; 10: 540662
    CrossrefPubMedGoogle Scholar
  • 5 Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?. Hepatobiliary Surg Nutr 2017; 6 (02) 105-116
    CrossrefPubMedGoogle Scholar
  • 6 National Comprehensive Cancer Network. Colon Cancer (Version 3.2023). Accessed April 4, 2024 at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf
    PubMedGoogle Scholar
  • 7 Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. The American Surgeon™ 2002; 68 (04) 395-397
    CrossrefPubMedGoogle Scholar
  • 8 Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol 2020; 9 (01) 8
    CrossrefPubMedGoogle Scholar
  • 9 Charalampopoulos G, Iezzi R, Tsitskari M. et al. Role of percutaneous ablation in the management of intrahepatic cholangiocarcinoma. Medicina (Kaunas) 2023; 59 (07) 1186
    CrossrefPubMedGoogle Scholar
  • 10 Pang C, Li J, Dou J. et al. Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study. EClinicalMedicine 2024; 67: 102336
    CrossrefPubMedGoogle Scholar
  • 11 Edeline J, Lamarca A, McNamara MG. et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev 2021; 99: 102258
    CrossrefPubMedGoogle Scholar
  • 12 Zhang K, Yu J, Yu X. et al. Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma. Int J Hyperthermia 2018; 34 (03) 292-297
    CrossrefPubMedGoogle Scholar
  • 13 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional treatment for cholangiocarcinoma. Front Oncol 2021; 11: 671327
    CrossrefPubMedGoogle Scholar
  • 14 Lin YM, Paolucci I, Brock KK, Odisio BC. Image-guided ablation for colorectal liver metastasis: principles, current evidence, and the path forward. Cancers (Basel) 2021; 13 (16) 3926
    CrossrefPubMedGoogle Scholar
  • 15 Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017; 6 (01) 2-6
    CrossrefPubMedGoogle Scholar
  • 16 Owen M, Makary MS, Beal EW. Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers (Basel) 2023; 15 (08) 2384
    CrossrefPubMedGoogle Scholar
  • 17 Bale R. Treatment of intrahepatic cholangiocarcinoma: evidence for the role of percutaneous ablation. Hepatoma Res 2023; 9: 44
    PubMedGoogle Scholar
  • 18 Giorgio A, Gatti P, Montesarchio L. et al. Intrahepatic cholangiocarcinoma and thermal ablation: long-term results of an Italian retrospective multicenter study. J Clin Transl Hepatol 2019; 7 (04) 287-292
    PubMedGoogle Scholar
  • 19 Belfiore MP, Reginelli A, Maggialetti N. et al. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy. Med Oncol 2020; 37 (05) 45
    CrossrefPubMedGoogle Scholar
  • 20 Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous image-guided cryoablation of hepatic tumors: single-center experience with intermediate to long-term outcomes. AJR Am J Roentgenol 2017; 209 (06) 1381-1389
    CrossrefPubMedGoogle Scholar
  • 21 Albuquerque J, Lin YM, Paolucci I. et al. Incidental ring-hyperenhancing liver micronodules at CT hepatic arteriography-guided percutaneous thermal ablation of colorectal liver metastases. Radiol Imaging Cancer 2024; 6 (02) e230099
    CrossrefPubMedGoogle Scholar
  • 22 Puijk RS, Ruarus AH, Scheffer HJ. et al. Percutaneous liver tumour ablation : image guidance, endpoint assessment, and quality control. Can Assoc Radiol J 2018; 69 (01) 51-62
    CrossrefPubMedGoogle Scholar
  • 23 Taiji R, Lin EY, Lin YM. et al. Combined angio-CT systems: a roadmap tool for precision therapy in interventional oncology. Radiol Imaging Cancer 2021; 3 (05) e210039
    CrossrefPubMedGoogle Scholar
  • 24 Odisio BC, Cox VL, Faria SC. et al. Prognostic value of incidental hypervascular micronodules detected on cone-beam computed tomography angiography of patients with liver metastasis. Eur Radiol 2017; 27 (11) 4837-4845
    CrossrefPubMedGoogle Scholar
  • 25 Tinguely P, Paolucci I, Ruiter SJS. et al. Stereotactic and robotic minimally invasive thermal ablation of malignant liver tumors: a systematic review and meta-analysis. Front Oncol 2021; 11: 713685
    CrossrefPubMedGoogle Scholar
  • 26 Yousaf A, Kim JU, Eliahoo J, Taylor-Robinson SD, Khan SA. Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Clin Exp Hepatol 2019; 9 (06) 740-748
    CrossrefPubMedGoogle Scholar
  • 27 Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2023; 73 (02) 198-222
    CrossrefPubMedGoogle Scholar
  • 28 Ahmed M, Solbiati L, Brace CL. et al; International Working Group on Image-guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology 2014; 273 (01) 241-260
    CrossrefPubMedGoogle Scholar
  • 29 Puijk RS, Ahmed M, Adam A. et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology 2021; 301 (03) 533-540
    CrossrefPubMedGoogle Scholar
  • 30 Kim GH, Kim PH, Kim JH. et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol 2022; 32 (02) 1205-1215
    CrossrefPubMedGoogle Scholar
  • 31 de Jong MC, Nathan H, Sotiropoulos GC. et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29 (23) 3140-3145
    CrossrefPubMedGoogle Scholar
  • 32 Laimer G, Schullian P, Jaschke N. et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol 2020; 30 (05) 2463-2472
    CrossrefPubMedGoogle Scholar
  • 33 Lin YM, Paolucci I, O'Connor CS. et al. Ablative margins of colorectal liver metastases using deformable CT image registration and autosegmentation. Radiology 2023; 307 (02) e221373
    CrossrefPubMedGoogle Scholar
  • 34 Paolucci I, Lin YM, Kawaguchi Y. et al. Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation. Br J Cancer 2023; 128 (01) 130-136
    CrossrefPubMedGoogle Scholar
  • 35 Anderson BM, Rigaud B, Lin YM. et al. Automated segmentation of colorectal liver metastasis and liver ablation on contrast-enhanced CT images. Front Oncol 2022; 12: 886517
    CrossrefPubMedGoogle Scholar
  • 36 Anderson BM, Lin YM, Lin EY. et al. A novel use of biomechanical model-based deformable image registration (DIR) for assessing colorectal liver metastases ablation outcomes. Med Phys 2021; 48 (10) 6226-6236
    CrossrefPubMedGoogle Scholar
  • 37 Chiou YY, Hwang JI, Chou YH, Wang HK, Chiang JH, Chang CY. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 2005; 21 (07) 304-309
    CrossrefPubMedGoogle Scholar
  • 38 Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011; 196 (02) W205-W209
    CrossrefPubMedGoogle Scholar
  • 39 Wu L, Tsilimigras DI, Farooq A. et al. Potential survival benefit of radiofrequency ablation for small solitary intrahepatic cholangiocarcinoma in nonsurgically managed patients: a population-based analysis. J Surg Oncol 2019; 120 (08) 1358-1364
    CrossrefPubMedGoogle Scholar
  • 40 Wang Y, Yuan Z, Liu B. et al. Long-term outcome and prognostic nomogram for intrahepatic cholangiocarcinoma after thermal ablation: a retrospective study. Transl Cancer Res 2020; 9 (11) 6743-6754
    CrossrefPubMedGoogle Scholar
  • 41 Braunwarth E, Schullian P, Kummann M. et al. Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma - stereotactic radiofrequency ablation as a valuable addition to hepatic resection. PLoS One 2022; 17 (01) e0261136
    CrossrefPubMedGoogle Scholar
  • 42 Haidu M, Dobrozemsky G, Schullian P. et al. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol 2012; 35 (05) 1074-1082
    CrossrefPubMedGoogle Scholar
  • 43 Yang GW, Zhao Q, Qian S. et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma. OncoTargets Ther 2015; 8: 1245-1250
    CrossrefPubMedGoogle Scholar
  • 44 Cho MT, Gholami S, Gui D. et al. Optimizing the diagnosis and biomarker testing for patients with intrahepatic cholangiocarcinoma: a multidisciplinary approach. Cancers (Basel) 2022; 14 (02) 392
    CrossrefPubMedGoogle Scholar
  • 45 Madoff DC, Abi-Jaoudeh N, Braxton D. et al. An expert, multidisciplinary perspective on best practices in biomarker testing in intrahepatic cholangiocarcinoma. Oncologist 2022; 27 (10) 884-891
    CrossrefPubMedGoogle Scholar
  • 46 Takahashi EA, Kinsman KA, Schmit GD. et al. Thermal ablation of intrahepatic cholangiocarcinoma: safety, efficacy, and factors affecting local tumor progression. Abdom Radiol (NY) 2018; 43 (12) 3487-3492
    CrossrefPubMedGoogle Scholar
  • 47 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) a2200015
    PubMedGoogle Scholar
  • 48 Woodhead G, Lee S, Struycken L, Goldberg D, Hannallah J, Young S. Interventional radiology locoregional therapies for intrahepatic cholangiocarcinoma. Life (Basel) 2024; 14 (02) 217
    PubMedGoogle Scholar
  • 49 Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168 (04) 707-723
    CrossrefPubMedGoogle Scholar
  • 50 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a Phase 2 clinical trial. JAMA Oncol 2020; 6 (01) 51-59
    CrossrefPubMedGoogle Scholar
  • 51 Yan X, Zhuang LP, Ning ZY, Wang P, Meng ZQ. Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Expert Rev Gastroenterol Hepatol 2022; 16 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 52 Chen B, Mao Y, Li J. et al. Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: a multi-institutional study. Comput Biol Med 2023; 167: 107612
    CrossrefPubMedGoogle Scholar
  • 53 Butros SR, Shenoy-Bhangle A, Mueller PR, Arellano RS. Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome. Clin Imaging 2014; 38 (04) 490-494
    CrossrefPubMedGoogle Scholar
  • 54 Ni JY, An C, Zhang TQ, Huang ZM, Jiang XY, Huang JH. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperthermia 2019; 36 (01) 328-336
    PubMedGoogle Scholar
  • 55 Xu C, Li L, Xu W. et al. Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results. Int J Hyperthermia 2019; 36 (01) 351-358
    CrossrefPubMedGoogle Scholar
  • 56 Brandi G, Rizzo A, Dall'Olio FG. et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperthermia 2020; 37 (01) 479-485
    CrossrefPubMedGoogle Scholar
  • 57 Díaz-González Á, Vilana R, Bianchi L. et al. Thermal ablation for intrahepatic cholangiocarcinoma in cirrhosis: safety and efficacy in non-surgical patients. J Vasc Interv Radiol 2020; 31 (05) 710-719
    CrossrefPubMedGoogle Scholar
  • 58 Yang H, Cheng Z, Han Z. et al. Assessment of the outcomes of intrahepatic cholangiocarcinoma after ultrasound-guided percutaneous microwave ablation based on albumin-bilirubin grade. Cardiovasc Intervent Radiol 2021; 44 (02) 261-270
    CrossrefPubMedGoogle Scholar
  • 59 Wang X, Liang P, Yu J. et al. Contrast-enhanced ultrasound features predict the prognosis of percutaneous microwave ablation of intrahepatic cholangiocarcinoma. Br J Radiol 2022; 95 (1133): 20211379
    CrossrefPubMedGoogle Scholar
  • 60 Warren EAK, Maithel SK. Molecular pathology for cholangiocarcinoma: a review of actionable genetic targets and their relevance to adjuvant & neoadjuvant therapy, staging, follow-up, and determination of minimal residual disease. Hepatobiliary Surg Nutr 2024; 13 (01) 29-38
    CrossrefPubMedGoogle Scholar
  • 61 Khosla D, Misra S, Chu PL. et al. Cholangiocarcinoma: recent advances in molecular pathobiology and therapeutic approaches. Cancers (Basel) 2024; 16 (04) 801
    CrossrefPubMedGoogle Scholar
  • 62 Li Y, Yu J, Zhang Y, Peng C, Song Y, Liu S. Advances in targeted therapy of cholangiocarcinoma. Ann Med 2024; 56 (01) 2310196
    CrossrefPubMedGoogle Scholar